361 related articles for article (PubMed ID: 34998839)
21. CCN5 overexpression inhibits profibrotic phenotypes via the PI3K/Akt signaling pathway in lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis and in an in vivo model of lung fibrosis.
Zhang L; Li Y; Liang C; Yang W
Int J Mol Med; 2014 Feb; 33(2):478-86. PubMed ID: 24276150
[TBL] [Abstract][Full Text] [Related]
22. DNA Methylome Alterations Are Associated with Airway Macrophage Differentiation and Phenotype during Lung Fibrosis.
McErlean P; Bell CG; Hewitt RJ; Busharat Z; Ogger PP; Ghai P; Albers GJ; Calamita E; Kingston S; Molyneaux PL; Beck S; Lloyd CM; Maher TM; Byrne AJ
Am J Respir Crit Care Med; 2021 Oct; 204(8):954-966. PubMed ID: 34280322
[No Abstract] [Full Text] [Related]
23. Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis.
Korfei M; Stelmaszek D; MacKenzie B; Skwarna S; Chillappagari S; Bach AC; Ruppert C; Saito S; Mahavadi P; Klepetko W; Fink L; Seeger W; Lasky JA; Pullamsetti SS; Krämer OH; Guenther A
PLoS One; 2018; 13(11):e0207915. PubMed ID: 30481203
[TBL] [Abstract][Full Text] [Related]
24. Nintedanib for the treatment of idiopathic pulmonary fibrosis.
Varone F; Sgalla G; Iovene B; Bruni T; Richeldi L
Expert Opin Pharmacother; 2018 Feb; 19(2):167-175. PubMed ID: 29327616
[TBL] [Abstract][Full Text] [Related]
25. Genetic alterations in squamous cell lung cancer associated with idiopathic pulmonary fibrosis.
Hata A; Nakajima T; Matsusaka K; Fukuyo M; Nakayama M; Morimoto J; Ito Y; Yamamoto T; Sakairi Y; Rahmutulla B; Ota S; Wada H; Suzuki H; Iwata T; Matsubara H; Ohara O; Yoshino I; Kaneda A
Int J Cancer; 2021 Jun; 148(12):3008-3018. PubMed ID: 33533494
[TBL] [Abstract][Full Text] [Related]
26. Nintedanib: a novel therapeutic approach for idiopathic pulmonary fibrosis.
Dimitroulis IA
Respir Care; 2014 Sep; 59(9):1450-5. PubMed ID: 24782550
[TBL] [Abstract][Full Text] [Related]
27. IDIOPATHIC PULMONARY FIBROSIS IS A COMPLEX GENETIC DISORDER.
Schwartz DA
Trans Am Clin Climatol Assoc; 2016; 127():34-45. PubMed ID: 28066036
[TBL] [Abstract][Full Text] [Related]
28. Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients.
Bondue B; Castiaux A; Van Simaeys G; Mathey C; Sherer F; Egrise D; Lacroix S; Huaux F; Doumont G; Goldman S
Respir Res; 2019 Jan; 20(1):10. PubMed ID: 30646908
[TBL] [Abstract][Full Text] [Related]
29. Histopathological and molecular analysis of idiopathic pulmonary fibrosis lungs from patients treated with pirfenidone or nintedanib.
Zhang Y; Jones KD; Achtar-Zadeh N; Green G; Kukreja J; Xu B; Wolters PJ
Histopathology; 2019 Jan; 74(2):341-349. PubMed ID: 30152895
[TBL] [Abstract][Full Text] [Related]
30. Interplay between EZH2 and G9a Regulates CXCL10 Gene Repression in Idiopathic Pulmonary Fibrosis.
Coward WR; Brand OJ; Pasini A; Jenkins G; Knox AJ; Pang L
Am J Respir Cell Mol Biol; 2018 Apr; 58(4):449-460. PubMed ID: 29053336
[TBL] [Abstract][Full Text] [Related]
31. Idiopathic pulmonary fibrosis: Addressing the current and future therapeutic advances along with the role of Sotatercept in the management of pulmonary hypertension.
Hadi DD; Marsool MDM; Marsool ADM; Vora N; Al-Badri SG; Al-Fatlawi NHK; Abbas Al Wssawi AF; Al-Ibraheem AMT; Hamza KA; Prajjwal P; Mateen MA; Amir O
Immun Inflamm Dis; 2023 Nov; 11(11):e1079. PubMed ID: 38018591
[TBL] [Abstract][Full Text] [Related]
32. Newer developments in idiopathic pulmonary fibrosis in the era of anti-fibrotic medications.
Nair GB; Matela A; Kurbanov D; Raghu G
Expert Rev Respir Med; 2016 Jun; 10(6):699-711. PubMed ID: 27094006
[TBL] [Abstract][Full Text] [Related]
33. Macrophage Implication in IPF: Updates on Immune, Epigenetic, and Metabolic Pathways.
Pokhreal D; Crestani B; Helou DG
Cells; 2023 Sep; 12(17):. PubMed ID: 37681924
[TBL] [Abstract][Full Text] [Related]
34. Transcriptomic and Epigenetic Profiling of Fibroblasts in Idiopathic Pulmonary Fibrosis.
Hanmandlu A; Zhu L; Mertens TCJ; Collum S; Bi W; Xiong F; Wang R; Amirthalingam RT; Ren D; Han L; Jyothula SSSK; Li W; Zheng WJ; Karmouty-Quintana H
Am J Respir Cell Mol Biol; 2022 Jan; 66(1):53-63. PubMed ID: 34370624
[TBL] [Abstract][Full Text] [Related]
35. Reversion of in vivo fibrogenesis by novel chromone scaffolds.
Kim HS; Yoon YM; Meang MK; Park YE; Lee JY; Lee TH; Lee JE; Kim IH; Youn BS
EBioMedicine; 2019 Jan; 39():484-496. PubMed ID: 30611717
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA-144-3p targets relaxin/insulin-like family peptide receptor 1 (RXFP1) expression in lung fibroblasts from patients with idiopathic pulmonary fibrosis.
Bahudhanapati H; Tan J; Dutta JA; Strock SB; Sembrat J; Àlvarez D; Rojas M; Jäger B; Prasse A; Zhang Y; Kass DJ
J Biol Chem; 2019 Mar; 294(13):5008-5022. PubMed ID: 30709904
[TBL] [Abstract][Full Text] [Related]
37. Genomic Fingerprint Associated with Familial Idiopathic Pulmonary Fibrosis: A Review.
Ding D; Gao R; Xue Q; Luan R; Yang J
Int J Med Sci; 2023; 20(3):329-345. PubMed ID: 36860670
[TBL] [Abstract][Full Text] [Related]
38. Epigenetic hallmarks in pulmonary fibrosis: New advances and perspectives.
Zhang YS; Tu B; Song K; Lin LC; Liu ZY; Lu D; Chen Q; Tao H
Cell Signal; 2023 Oct; 110():110842. PubMed ID: 37544633
[TBL] [Abstract][Full Text] [Related]
39. Altered DNA methylation profile in idiopathic pulmonary fibrosis.
Sanders YY; Ambalavanan N; Halloran B; Zhang X; Liu H; Crossman DK; Bray M; Zhang K; Thannickal VJ; Hagood JS
Am J Respir Crit Care Med; 2012 Sep; 186(6):525-35. PubMed ID: 22700861
[TBL] [Abstract][Full Text] [Related]
40. MicroRNAs in idiopathic pulmonary fibrosis, new research progress and their pathophysiological implication.
Miao C; Xiong Y; Zhang G; Chang J
Exp Lung Res; 2018 Apr; 44(3):178-190. PubMed ID: 29683754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
